CCO Oncology Podcast

Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

Episode Summary

Listen to Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, as they answer audience questions from a live webinar about how to best use the plethora of active agents and regimens now available for patients with advanced multiple myeloma.

Episode Notes

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:

• Treatment after first relapsed
• Optimal use of CAR T-cell therapy
• When to use selinexor and belantamab mafodotin
• COVID-19 vaccinations for patients with myeloma

Presenters:

Paul G. Richardson, MD
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Peter M. Voorhees, MD
Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.

Link to full program:
https://bit.ly/2UIhXcL